Evidence map›Paper›PMID 26313897›Full record

ReviewCurrent opinion in endocrinology, diabetes, and obesity2015

Leptin applications in 2015: what have we learned about leptin and obesity?

Olivia M Farr, Anna Gavrieli, Christos S Mantzoros

Registry-linked trialAbstract readReview
In one paragraph

Review in Current opinion in endocrinology, diabetes, and obesity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04443790 (Obesity Control Through Leptogenic Drugs), which is not on this map. Cited by 105 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 4 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04443790 phase2completednot on this map

Obesity Control Through Leptogenic Drugs

TypeinterventionalSponsorHafiz Muhammad AsifRan2015 to 2018Enrolled132ConditionsLeptin Deficiency, ObesityArmsLeptin Human
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 4 syntheses or guidelines pooled it, 229 citations in OpenAlex.

  1. Is hyperleptinemia associated with gallstone disease? A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. History of Breastfeeding in Relation to Circulating Inflammatory and Metabolic Biomarkers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  18. Article
  19. Article
  20. Leptin levels are associated with body mass index and Alzheimer's disease in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Olivia M FarrDivision of Endocrinology, Boston VA Healthcare System/Harvard Medical School Section of Endocrinology, Beth-Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, USA *Olivia M. Farr and Anna Gavrieli authors have contributed equally to the writing of this article.
Anna Gavrieli
Christos S Mantzoros
Beth Israel Deaconess Medical Center · US

Funding

Training Program in Nutrition and MetabolismT32HD052961 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN K. · 2005 to 2016
$1.3M
Leptin Signaling in HumansI01CX000422 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MANTZOROS, CHRISTOS S · 2011 to 2014
–
CSRD VA I01 CX000422NICHD NIH HHS 5T32HD052961NICHD NIH HHS T32 HD052961
6 · The paper itself

Abstract

purpose of reviewTo summarize previous and current advancements for leptin therapeutics, we described how leptin may be useful in leptin deficient states such as lipodystrophy, for which leptin was recently approved, and how it may be useful in the future for typical obesity. RECENT

findingsThe discovery of leptin in 1994 built the foundation for understanding the pathophysiology and treatment of obesity. Leptin therapy reverses morbid obesity related to congenital leptin deficiency and appears to possibly treat lipodystrophy, a finding which has led to the approval of leptin for the treatment of lipodystrophy in the USA and Japan. Typical obesity, on the other hand, is characterized by hyperleptinemia and leptin tolerance. Thus, leptin administration has proven ineffective for inducing weight loss on its own but could possibly be useful in combination with other therapies or for weight loss maintenance. SUMMARY: Leptin is not able to treat typical obesity; however, it is effective for reversing leptin deficiency-induced obesity and is possibly useful in lipodystrophy. New mechanisms and pathways involved in leptin resistance are continuously discovered, whereas the development of new techniques and drug combinations which may improve leptin's efficacy and safety regenerate the hope for its use as an effective treatment for typical obesity.

Indexed as

AnimalsHumansLeptinLipodystrophyObesityLeptin

Identifiers

PMID26313897
PMCPMC4610373
OpenAlexW2419587660

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.